Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Lucentis in Advanced Macular Degeneration

Authors not listed

Steven R. Sanislo · 2009

Abstract

Patients with low vision (visual acuity 20/400 or worse) were excluded from the large Phase III ranibizumab clinical trials. It is not known if treatment with ranibizumab results in improved visual function in such patients.Since ranibizumab has been shown to be the most effective therapy for exudative macular degeneration we propose to treat all patients in this study with monthly ranibizumab intravitreal injections. Patients will be assigned to one of two groups by the flip of a coin. Group #1 for "heads" and Group #2 for "tails". Group #1 patients will be treated for 3 monthly injections of 0.5 mg of ranibizumab and then as needed therapy. Group #2 will be treated with 6 monthly injections of 0.5 mg of ranibizumab and then as needed therapy.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-15 MST

Cite this

APA
Anonymous. (2009). Lucentis in Advanced Macular Degeneration. <em>Steven R. Sanislo</em>. https://clinicaltrials.gov/study/NCT00896779
Vancouver
Anonymous. Lucentis in Advanced Macular Degeneration. Steven R. Sanislo. 2009.
BibTeX
@misc{anon2009Lucent, title = {Lucentis in Advanced Macular Degeneration}, author = {Anonymous}, journal = {Steven R. Sanislo}, year = {2009}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings